Compare AVAV & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | BIO |
|---|---|---|
| Founded | 1971 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.1B |
| IPO Year | 2006 | 1994 |
| Metric | AVAV | BIO |
|---|---|---|
| Price | $118.22 | $373.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 3 |
| Target Price | $212.20 | ★ $335.00 |
| AVG Volume (30 Days) | ★ 1.3M | 208.6K |
| Earning Date | 12-08-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,583,200,000.00 |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $15.34 | $2.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $113.15 | $236.73 |
| 52 Week High | $408.25 | $396.23 |
| Indicator | AVAV | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 53.33 |
| Support Level | $113.15 | $364.41 |
| Resistance Level | $165.15 | $391.87 |
| Average True Range (ATR) | 6.49 | 11.42 |
| MACD | 1.26 | 1.18 |
| Stochastic Oscillator | 41.06 | 64.43 |
AeroVironment Inc is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploys autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. The company operates business in two reportable segments: Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE). It derives majority of revenue from Autonomous Systems segment focuses on the design, development, production, delivery, and support of intelligent, multi-domain robotic systems, including UAS, uncrewed underwater vehicles and ground robot systems. Geographically it derives the majority of revenue from domestic operations.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.